JPH09241156A - Blood flow promotor and preparation for external use for skin containing the same - Google Patents
Blood flow promotor and preparation for external use for skin containing the sameInfo
- Publication number
- JPH09241156A JPH09241156A JP7966696A JP7966696A JPH09241156A JP H09241156 A JPH09241156 A JP H09241156A JP 7966696 A JP7966696 A JP 7966696A JP 7966696 A JP7966696 A JP 7966696A JP H09241156 A JPH09241156 A JP H09241156A
- Authority
- JP
- Japan
- Prior art keywords
- arginine
- blood flow
- ester
- acid
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000017531 blood circulation Effects 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 229930064664 L-arginine Natural products 0.000 claims abstract description 40
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 40
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 239000002537 cosmetic Substances 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 229930182558 Sterol Natural products 0.000 claims abstract description 9
- 235000003702 sterols Nutrition 0.000 claims abstract description 9
- 210000004761 scalp Anatomy 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 229930186217 Glycolipid Natural products 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims abstract description 3
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims abstract description 3
- -1 alkenyl ester Chemical class 0.000 claims description 46
- 210000004209 hair Anatomy 0.000 claims description 15
- 230000001737 promoting effect Effects 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 6
- 230000003712 anti-aging effect Effects 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 abstract description 6
- 150000003432 sterols Chemical class 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 125000003342 alkenyl group Chemical group 0.000 abstract description 3
- 150000003904 phospholipids Chemical class 0.000 abstract description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 15
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000003779 hair growth Effects 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- 206010040954 Skin wrinkling Diseases 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229920001059 synthetic polymer Polymers 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 235000017788 Cydonia oblonga Nutrition 0.000 description 3
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 241000218657 Picea Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 238000005809 transesterification reaction Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 150000002339 glycosphingolipids Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- HMDUQDMYHUOZDP-LBPRGKRZSA-N octyl (2s)-2-amino-5-(diaminomethylideneamino)pentanoate Chemical compound CCCCCCCCOC(=O)[C@@H](N)CCCN=C(N)N HMDUQDMYHUOZDP-LBPRGKRZSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- JPWUIQIFCDAWQX-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(O)CO JPWUIQIFCDAWQX-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 240000004731 Acer pseudoplatanus Species 0.000 description 1
- 235000002754 Acer pseudoplatanus Nutrition 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- BEPMEJAUKUPADL-LBPRGKRZSA-N C1(=CC=CC=C1)CCOC([C@@H](N)CCCNC(N)=N)=O Chemical compound C1(=CC=CC=C1)CCOC([C@@H](N)CCCNC(N)=N)=O BEPMEJAUKUPADL-LBPRGKRZSA-N 0.000 description 1
- YTFAANNRKOWUTI-UHFFFAOYSA-N CCCCCCCCCC(CCCCCC)OC(=O)CCCCC(O)=O Chemical compound CCCCCCCCCC(CCCCCC)OC(=O)CCCCC(O)=O YTFAANNRKOWUTI-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 241000510032 Ellipsaria lineolata Species 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 235000005491 Geranium thunbergii Nutrition 0.000 description 1
- 244000105059 Geranium thunbergii Species 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- KIENGQUGHPTFGC-JLAZNSOCSA-N L-ascorbic acid 6-phosphate Chemical compound OP(=O)(O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O KIENGQUGHPTFGC-JLAZNSOCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 244000208060 Lawsonia inermis Species 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 235000006485 Platanus occidentalis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000002953 Saxifraga stolonifera Nutrition 0.000 description 1
- 244000288377 Saxifraga stolonifera Species 0.000 description 1
- 229940122511 Sebum inhibitor Drugs 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 240000000377 Tussilago farfara Species 0.000 description 1
- 235000004869 Tussilago farfara Nutrition 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- RKFMOTBTFHXWCM-UHFFFAOYSA-M [AlH2]O Chemical compound [AlH2]O RKFMOTBTFHXWCM-UHFFFAOYSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- FYGDTMLNYKFZSV-ZWSAEMDYSA-N cellotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ZWSAEMDYSA-N 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 1
- OJAOCVYPSWZSRT-INIZCTEOSA-N dodecyl (2s)-2-amino-5-(diaminomethylideneamino)pentanoate Chemical compound CCCCCCCCCCCCOC(=O)[C@@H](N)CCCNC(N)=N OJAOCVYPSWZSRT-INIZCTEOSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 150000002298 globosides Chemical class 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 150000002948 pantothenic acids Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 125000005539 phosphatidic acid group Chemical group 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- HLWRUJAIJJEZDL-UHFFFAOYSA-M sodium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC([O-])=O HLWRUJAIJJEZDL-UHFFFAOYSA-M 0.000 description 1
- KJCLYACXIWMFCC-UHFFFAOYSA-M sodium;5-benzoyl-4-hydroxy-2-methoxybenzenesulfonate Chemical compound [Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 KJCLYACXIWMFCC-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical class NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- IFYFNVDTVZKNBZ-UHFFFAOYSA-N tetradecyl 2-hydroxybenzoate Chemical compound CCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1O IFYFNVDTVZKNBZ-UHFFFAOYSA-N 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は経時安定性、安全
性、経皮吸収性及び細胞膜親和性に優れた血流促進剤及
びそれを有効成分として配合した皮膚外用剤、化粧料特
に老化防止用化粧料、頭皮用化粧料、養毛・育毛剤に関
する。TECHNICAL FIELD The present invention relates to a blood flow promoter having excellent stability over time, safety, percutaneous absorption and affinity for cell membranes, and a skin external preparation containing the same as an active ingredient, a cosmetic, especially for antiaging. The present invention relates to cosmetics, scalp cosmetics, and hair-growth / hair-growth agents.
【0002】[0002]
【従来の技術】従来、美肌作用を有するものとして種々
の成分が皮膚外用剤及び化粧料に用いられてきた。この
中で、血流促進剤は、真皮及び表皮細胞への血流を促進
することにより、真皮線維芽細胞を賦活化してしわの発
生を防止したり、しわの改善効果を発揮したり、皮膚細
胞層への栄養成分や水分を充分に補給し組織内からエモ
リエント効果,保湿効果を発揮したり、新陳代謝が活発
になることによりくすみを改善する効果を発揮する。2. Description of the Related Art Heretofore, various components have been used in external preparations for skin and cosmetics as those having a skin beautifying effect. Among these, the blood flow promoting agent, by promoting the blood flow to the dermis and epidermal cells, to activate the dermal fibroblasts to prevent the generation of wrinkles, or to exert the effect of improving wrinkles, skin It provides emollient and moisturizing effects from within tissues by adequately replenishing nutrients and water to the cell layer, and improves dullness by activating metabolism.
【0003】また、ふけ、かゆみ、脱毛等の頭皮にかか
る種々の疾患の原因のひとつとして、頭皮の血流不良が
指摘されており、血流促進効果を有する皮膚外用剤の適
用がなされてきた。Poor blood flow in the scalp has been pointed out as one of the causes of various diseases related to the scalp such as dandruff, itch, and hair loss, and an external preparation for skin having a blood flow promoting effect has been applied. .
【0004】さらに、養毛・育毛を目的とする養毛・育
毛剤には、従来から酢酸dl−α−トコフェロールなど
の合成化学物質やセンブリ抽出液等の血流促進剤が有効
成分として用いられてきた。[0004] Further, synthetic hairs such as dl-α-tocopheryl acetate and blood flow promoters such as cembly extract have been used as active ingredients for hair growth and hair growth agents for hair growth and hair growth. Came.
【0005】一方、L−アルギニンは、NO合成酵素と
反応し、血流促進効果を有するNOラジカルを生成する
ことが知られている(化学と工業,Vol.48No.5,1
995)。そこで、アルギニン及びそのアルキルエステ
ルを有効成分とする養毛剤(WO94/09750)、
アルギニン及びそのエステルを配合した化粧料(WO9
5/15147)が開示されている。On the other hand, L-arginine is known to react with NO synthase to produce NO radicals having a blood flow promoting effect (Chemicals and Industry, Vol. 48 No. 5, 1).
995). Therefore, a hair nourishing agent (WO94 / 09750) containing arginine and its alkyl ester as an active ingredient,
Cosmetics containing arginine and its ester (WO9
5/15147) is disclosed.
【0006】[0006]
【発明が解決しようとする課題】しかしながら、L−ア
ルギニンは塩基性のアミノ酸であり、血流促進剤等の有
効成分として使用するには、経皮で皮膚刺激の原因とな
ったり、安定な製剤が得られない等の問題があった。However, L-arginine, which is a basic amino acid, causes skin irritation by percutaneous use and is a stable preparation for use as an active ingredient such as a blood flow promoter. There was a problem such as not being able to obtain.
【0007】さらに、L−アルギニンは、水溶性の性質
を有しているため、細胞膜透過性が低く、皮膚外用剤等
の製剤に配合して経皮投与を行っても、有効量のL−ア
ルギニンを配合することは困難であった。Furthermore, since L-arginine has a water-soluble property, it has low cell membrane permeability, and even if it is transdermally administered to a preparation such as a skin external preparation, an effective amount of L-arginine is obtained. It was difficult to mix arginine.
【0008】そこで、本発明はこのような課題を解決
し、経皮投与した場合の安全性及び経時安定性が良好
で、高い細胞膜親和性を有し、経皮吸収性に優れた血流
促進剤、皮膚外用剤、老化防止用化粧料、頭皮用化粧
料、養毛・育毛剤を得ることを目的とした。Therefore, the present invention has solved such problems, has good safety and stability over time when transdermally administered, has a high affinity for cell membranes, and promotes blood flow with excellent transdermal absorbability. The purpose of the present invention is to obtain an agent for external use on the skin, a cosmetic for preventing aging, a cosmetic for scalp, and a hair nourishing / hair-growing agent.
【0009】[0009]
【課題を解決するための手段】本発明の課題を解決する
ため本発明においては、L−アルギニンの炭素数6〜2
0のアルキル若しくはアルケニルエステル、リン脂質エ
ステル、スフィンゴシン及びその誘導体のエステル、糖
脂質エステル、糖エステル、ステロールエステルを有効
成分とする血流促進剤を用いた。In order to solve the problems of the present invention, in the present invention, L-arginine has 6 to 2 carbon atoms.
A blood flow promoting agent containing an alkyl or alkenyl ester of 0, phospholipid ester, ester of sphingosine and its derivative, glycolipid ester, sugar ester, and sterol ester as active ingredients was used.
【0010】L−アルギニンのアルキル若しくはアルケ
ニルエステルに用いられるアルキル基,アルケニル基と
しては、炭素数6〜20の分岐又は直鎖のアルキル基若
しくはアルケニル基が挙げらる。このようなL−アルギ
ニンのアルキルエステルとしては、L−アルギニンオク
チルエステルのような直鎖脂肪族エステル、L−アルギ
ニンイソステアリルエステルのような分岐鎖脂肪族エス
テル、L−アルギニンフェニルエチルエステルのような
フェニルアルキルエステル等が、アルケニルエステルと
してはL−アルギニンオレイルエステル等が例示され
る。Examples of the alkyl group and alkenyl group used for the alkyl or alkenyl ester of L-arginine include a branched or linear alkyl group or alkenyl group having 6 to 20 carbon atoms. Examples of the alkyl ester of L-arginine include straight chain aliphatic esters such as L-arginine octyl ester, branched chain aliphatic esters such as L-arginine isostearyl ester, and L-arginine phenylethyl ester. Phenyl alkyl ester and the like are exemplified, and as alkenyl ester, L-arginine oleyl ester and the like are exemplified.
【0011】L−アルギニンのリン脂質エステルに用い
られるリン脂質としては、ホスファチジン酸,ホスファ
チジルエタノールアミン,ホスファチジルセリン,ホス
ファチジルイノシトール,ホスファチジルグリセロー
ル,ホスファチジルコリン等のグリセロリン脂質があげ
られる。Examples of the phospholipid used for the phospholipid ester of L-arginine include glycerophospholipids such as phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol and phosphatidylcholine.
【0012】さらに、L−アルギニンのリン脂質エステ
ルに用いられるリン脂質としては、スフィンゴミエリ
ン,セラミドホスホエタノールアミン,セラミドホスホ
イノシトールのようなスフィンゴリン脂質を用いること
もできる。Further, as the phospholipid used for the phospholipid ester of L-arginine, sphingolipids such as sphingomyelin, ceramide phosphoethanolamine and ceramide phosphoinositol can be used.
【0013】L−アルギニンの糖脂質エステルに用いら
れる糖脂質としては、グリセロ糖脂質,スフィンゴ糖脂
質のいずれでも良い。グリセロ糖脂質としては、モノア
シルグリコシルグリセロール,ジアシルガラクトシルグ
リセロール,グルコサミニルホスファチジルグリセロー
ル等が、また、スフィンゴ糖脂質の例としては、セレブ
ロシド類,スルファチド類,セラミドオリゴヘキソシド
類,グロボシド類,ガングリオシド類等が挙げられる。The glycolipid used in the glycolipid ester of L-arginine may be either a glyceroglycolipid or a glycosphingolipid. Glyceroglycolipids include monoacylglycosylglycerol, diacylgalactosylglycerol, glucosaminylphosphatidylglycerol, and examples of glycosphingolipids include cerebrosides, sulfatides, ceramide oligohexosides, globosides, gangliosides. And the like.
【0014】L−アルギニンの糖エステルに用いられる
糖としては、細胞膜親和性の点から単糖類又は二糖類〜
三糖類くらいのオリゴ糖が好ましい。本発明の目的に
は、エリスロース,トレオース等のテトロース類、アラ
ビノース,キシロース,リボース等のペントース類、ガ
ラクトース,グルコース,マンノース,プシコース,フ
ルクトース等のヘキソース類、N-アセチルガラクトサミ
ン,N-アセチルグルコサミン,マンノサミン等のアミノ
糖類、マルトース,ラクトース,ショ糖,セロビオース
等の二糖類、セロトリオース等の三糖類などが例示され
る。The sugar used in the sugar ester of L-arginine is a monosaccharide or disaccharide from the viewpoint of cell membrane affinity.
Oligosaccharides such as trisaccharides are preferred. For the purpose of the present invention, tetroses such as erythrose and threose, pentoses such as arabinose, xylose and ribose, hexoses such as galactose, glucose, mannose, psicose and fructose, N-acetylgalactosamine, N-acetylglucosamine, Examples include amino sugars such as mannosamine, disaccharides such as maltose, lactose, sucrose and cellobiose, and trisaccharides such as cellotriose.
【0015】L−アルギニンのステロールエステルに用
いられるステロールとしては、動物起源のもの,植物起
源のもの及び合成によるもののいずれを用いても良い。
かかるステロールとしては、コレステロール,ラノステ
ロール,フィトステロール,シトステロール,スチグマ
ステロール,カンペステロール,デスモステロール及び
これらステロールの誘導体等を挙げることができる。The sterol used in the sterol ester of L-arginine may be of animal origin, plant origin or synthetic origin.
Examples of such sterols include cholesterol, lanosterol, phytosterol, sitosterol, stigmasterol, campesterol, desmosterol, and derivatives of these sterols.
【0016】以上例示したアルギニンのエステル類は、
従来公知のエステル化反応又はエステル交換反応により
合成することができる。The arginine esters exemplified above are:
It can be synthesized by a conventionally known esterification reaction or transesterification reaction.
【0017】たとえば、L−アルギニンのホスファチジ
ルエステルは、ホスホリパーゼA1によるエステル交換
反応により、効率よくホスファチジン酸の1位にエステ
ル結合させることができる。For example, a phosphatidyl ester of L-arginine can be efficiently ester-bonded to the 1-position of phosphatidic acid by a transesterification reaction with phospholipase A1.
【0018】また、L−アルギニンの糖エステルは、た
とえばL−アルギニンをエステル化し、これと糖とを水
酸化ナトリウム等のアルカリ触媒存在下にて反応させ、
エステル交換反応等により合成することができる。な
お、副生成物のアルコールを系から除去すると、反応を
効率よく進ませることができる。The sugar ester of L-arginine is obtained by, for example, esterifying L-arginine, and reacting this with sugar in the presence of an alkali catalyst such as sodium hydroxide.
It can be synthesized by a transesterification reaction or the like. When the alcohol by-product is removed from the system, the reaction can proceed efficiently.
【0019】さらに、L−アルギニンのステロールエス
テルは、たとえば無触媒又はパラトルエンスルホン酸,
塩化スズ等の触媒の存在下に、L−アルギニン及びステ
ロールの混合物を約100〜250℃程度に加熱すれば
よい。この反応の終点は、酸価を測定することにより知
ることができる。Further, the sterol ester of L-arginine is, for example, uncatalyzed or paratoluenesulfonic acid,
The mixture of L-arginine and sterol may be heated to about 100 to 250 ° C. in the presence of a catalyst such as tin chloride. The end point of this reaction can be known by measuring the acid value.
【0020】[0020]
【発明の実施の形態】本発明において、上記L−アルギ
ニンエステルを有効成分とする血流促進剤の皮膚外用
剤,化粧料,養毛剤等への配合量は、0.1〜5重量%
が適当である。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, the amount of the blood flow promoting agent containing the above-mentioned L-arginine ester as an active ingredient in skin external preparations, cosmetics, hair nourishing agents, etc. is 0.1 to 5% by weight.
Is appropriate.
【0021】本発明にかかる皮膚外用剤,化粧料,養毛
剤等は、ローション,油剤,乳剤,クリーム,軟膏等の
剤型を、またボトル,ジャー,チューブ,フォーム,ゲ
ル,スプレー等の形態をとることができる。また、本発
明における皮膚外用剤等の適用部位は、顔面及び頭皮の
みならず、肩,腕,腹,背中,脚部等全身に使用でき
る。The external preparation for skin, cosmetics, hair nourishing agent and the like according to the present invention takes the form of lotions, oils, emulsions, creams, ointments and the like, and forms such as bottles, jars, tubes, foams, gels and sprays. be able to. Further, the application site of the external preparation for skin or the like in the present invention can be used not only on the face and scalp but also on the whole body such as shoulders, arms, abdomen, back and legs.
【0022】本発明においてはさらに必要に応じて、本
発明の効果を損なわない範囲で、化粧品、医薬品等に一
般に用いられている各種成分、すなわち、アボカド油,
パーム油,ピーナッツ油,コメヌカ油,ホホバ油,オレ
ンジラフィー油,マカデミアナッツ油,スクワラン,月
見草油,セサミ油,サンフラワー油,サフラワー油,キ
ャローラ油,カルナウバワックス,パラフィンワック
ス,ラノリン,リンゴ酸ジイソステアリル,イソステア
リルアルコール,流動パラフィン等の油分、グリセリ
ン,ジグリセリン,ポリグリセリン,ソルビット,ポリ
エチレングリコール,1,3-ブチレングリコール,コラー
ゲン,ヒアルロン酸等の保湿剤、ビタミンA油,レチノ
ール,酢酸レチノール等のビタミンA類、リボフラビ
ン,酪酸リボフラビン等のビタミンB2類、塩酸ピリドキ
シン等のビタミンB6類、L−アスコルビン酸,L−アス
コルビルリン酸マグネシウム,L−アスコルビン酸ナト
リウム等のビタミンC類、パントテン酸カルシウム,パ
ントテニルアルコール,パントテニルエチルエーテル,
アセチルパントテニルエチルエーテル等のパントテン酸
類、エルゴカルシフェロール,コレカルシフェロール等
のビタミンD類、ニコチン酸,ニコチン酸アミド,ニコ
チン酸ベンジル等のニコチン酸類、α−トコフェロー
ル,酢酸トコフェロール等のビタミンE類、ビタミンP、
ビオチン等のビタミン類、2−ヒドロキシ−4−メトキ
シベンゾフェノン,2−ヒドロキシ−4−メトキシベン
ゾフェノン−5−スルホン酸,2−ヒドロキシ−4−メ
トキシベンゾフェノン−5−スルホン酸ナトリウム等の
ベンゾフェノン誘導体、パラアミノ安息香酸,パラアミ
ノ安息香酸エチル,パラジメチルアミノ安息香酸オクチ
ル等のパラアミノ安息香酸誘導体、パラメトキシ桂皮酸
−2−エチルヘキシル,ジパラメトキシ桂皮酸モノ−2
−エチルヘキサン酸グリセリル等のメトキシ桂皮酸誘導
体類、サリチル酸オクチル,サリチル酸ミリスチル等の
サリチル酸誘導体、ウロカニン酸、4−tert−ブチルー
4'ーメトキシジベンゾイルメタン、2−(2'−ヒドロ
キシ−5'−メチルフェニル)ベンゾトリアゾール等の
紫外線吸収剤、グアガム,ローカストビーンガム,カラ
ギーナン,クインスシード,ペクチン,マンナン等の植
物系天然多糖類、キサンタンガム,デキストラン,カー
ドラン等の微生物系天然多糖類、ゼラチン,カゼイン,
アルブミン,コラーゲン等の動物系高分子、メチルセル
ロース,エチルセルロース,ヒドロキシエチルセルロー
ス,ヒドロキシプロピルセルロース,カルボキシメチル
セルロース等のセルロース系半合成高分子、可溶性デン
プン,カルボキシメチルデンプン,メチルデンプン等の
デンプン系半合成高分子、アルギン酸プロピレングリコ
ールエステル,アルギン酸塩等のアルギン酸系半合成高
分子、ポリビニルアルコール,ポリビニルピロリドン,
カルボキシビニルポリマー,ポリアクリル酸ナトリウ
ム,ポリエチレンオキサイド等の合成高分子、ベントナ
イト,ラポナイト,コロイダルアルミナ等の無機物系高
分子等の水溶性高分子、ジブチルヒドロキシトルエン,
ブチルヒドロキシアニソール,没食子酸エステル等の酸
化防止剤、高級脂肪酸石鹸,アルキル硫酸エステル塩,
ポリオキシエチレンアルキルエーテル硫酸塩,アシルメ
チルタウリン塩,アルキルエーテルリン酸エステル塩,
アシルアミノ酸塩等のアニオン界面活性剤、塩化アルキ
ルトリメチルアンモニウム,塩化ジアルキルジメチルア
ンモニウム,塩化ベンザルコニウム等のカチオン界面活
性剤、アルキルジメチルアミノ酢酸ベタイン,アルキル
アミドジメチルアミノ酢酸ベタイン,2−アルキル−N
−カルボキシメチル−N−ヒドロキシエチルイミダゾリ
ニウムベタインなどの両性界面活性剤、ポリオキシエチ
レン型ノニオン界面活性剤、アルコールエステル型ノニ
オン界面活性剤等の界面活性剤、エチレンジアミン四酢
酸ナトリウム塩,ポリリン酸ナトリウム,クエン酸,メ
タリン酸ナトリウム,コハク酸,グルコン酸等の金属イ
オン封鎖剤、胎盤抽出物,ソウハクヒエキス,グルタチ
オン,コウジ酸及びその誘導体類,ハイドロキノン配糖
体等のハイドロキノン及びその誘導体類等の美白剤、グ
リチルリチン酸,グリチルレチン酸,アラントイン,ア
ズレン,ヒドロコルチゾン,ε−アミノカプロン酸等の
抗炎症剤、酸化亜鉛,アラントインヒドロキシアルミニ
ウム,塩化アルミニウム,タンニン酸,クエン酸,乳酸
等の収れん剤、ミノキシジル,セファランチン,塩化カ
ルプロニウム,ノニル酸バニルアミド等の育毛・養毛成
分、メントール,カンフル等の清涼化剤、塩酸ジフェン
ヒドラミン,マレイン酸クロルフェニラミン等の抗ヒス
タミン剤、エストラジオール,エストロン,エチニルエ
ストラジオール等の皮脂抑制剤、サリチル酸,レゾルシ
ン等の角質剥離・溶解剤、パラヒドロキシ安息香酸エチ
ル,パラヒドロキシ安息香酸メチル,パラヒドロキシ安
息香酸ブチル,パラヒドロキシ安息香酸プロピル,エチ
レングリコールモノフェニルエーテル等の抗菌防腐剤、
グリセリン,カンファー等の温感剤、α−ヒドロキシ酸
類等が配合できる。In the present invention, if necessary, various components generally used in cosmetics, pharmaceuticals, etc., that is, avocado oil, within a range that does not impair the effects of the present invention,
Palm oil, peanut oil, rice bran oil, jojoba oil, orange luffy oil, macadamia nut oil, squalane, evening primrose oil, sesame oil, sunflower oil, safflower oil, carola oil, carnauba wax, paraffin wax, lanolin, dimalate Oil components such as isostearyl, isostearyl alcohol, liquid paraffin, glycerin, diglycerin, polyglycerin, sorbit, polyethylene glycol, 1,3-butylene glycol, collagen, moisturizers such as hyaluronic acid, vitamin A oil, retinol, retinol acetate vitamin a, riboflavin, vitamin B 2 such as riboflavin butyrate and the like, vitamin B 6 such as pyridoxine hydrochloride, L- ascorbic acid, magnesium L- ascorbyl phosphate, vitamin C such as sodium L- ascorbate , Calcium pantothenate, pantothenyl alcohol, pantothenyl ethyl ether,
Pantothenic acids such as acetyl pantothenyl ethyl ether, vitamin Ds such as ergocalciferol, cholecalciferol, nicotinic acids such as nicotinic acid, nicotinic acid amide, benzyl nicotinate, vitamin Es such as α-tocopherol and tocopherol acetate, Vitamin P,
Vitamin such as biotin, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid, benzophenone derivative such as sodium 2-hydroxy-4-methoxybenzophenone-5-sulfonate, para-aminobenzoic acid Acid, paraaminobenzoic acid derivatives such as ethyl paraaminobenzoate, octyl paradimethylaminobenzoate, 2-ethylhexyl paramethoxycinnamate, mono-2 diparamethoxycinnamic acid
-Methoxycinnamic acid derivatives such as glyceryl ethylhexanoate, salicylic acid derivatives such as octyl salicylate and myristyl salicylate, urocanic acid, 4-tert-butyl-4'-methoxydibenzoylmethane, 2- (2'-hydroxy-5'- UV absorbers such as methylphenyl) benzotriazole, natural plant polysaccharides such as guar gum, locust bean gum, carrageenan, quince seed, pectin and mannan, microbial natural polysaccharides such as xanthan gum, dextran and curdlan, gelatin, casein ,
Animal-based polymers such as albumin and collagen, cellulosic semi-synthetic polymers such as methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and carboxymethyl cellulose, and starch-based semi-synthetic polymers such as soluble starch, carboxymethyl starch and methyl starch, Alginic acid propylene glycol ester, alginic acid-based semi-synthetic polymers such as alginate, polyvinyl alcohol, polyvinylpyrrolidone,
Synthetic polymers such as carboxyvinyl polymer, sodium polyacrylate, polyethylene oxide, water-soluble polymers such as bentonite, laponite, inorganic polymers such as colloidal alumina, dibutylhydroxytoluene,
Butyl hydroxyanisole, antioxidants such as gallic acid ester, higher fatty acid soap, alkyl sulfate ester salt,
Polyoxyethylene alkyl ether sulfate, acylmethyl taurine salt, alkyl ether phosphate salt,
Anionic surfactants such as acylamino acid salts, cationic surfactants such as alkyltrimethylammonium chloride, dialkyldimethylammonium chloride, and benzalkonium chloride, alkyldimethylaminoacetic acid betaine, alkylamide dimethylaminoacetic acid betaine, 2-alkyl-N
-Carboxymethyl-N-hydroxyethylimidazolinium betaine and other amphoteric surfactants, polyoxyethylene type nonionic surfactants, alcohol ester type nonionic surfactants and other surfactants, ethylenediaminetetraacetic acid sodium salt, sodium polyphosphate , Whitening of sequestering agents such as citric acid, sodium metaphosphate, succinic acid, gluconic acid, placenta extract, sow syrup extract, glutathione, kojic acid and its derivatives, hydroquinone such as hydroquinone glycoside and its derivatives Agents, anti-inflammatory agents such as glycyrrhizinic acid, glycyrrhetinic acid, allantoin, azulene, hydrocortisone, and ε-aminocaproic acid, astringents such as zinc oxide, allantoin hydroxyaluminum, aluminum chloride, tannic acid, citric acid, and lactic acid; Hair growth and nourishing ingredients such as xidyl, cepharanthin, carpronium chloride, nonyl acid vanilamide, refreshing agents such as menthol and camphor, antihistamines such as diphenhydramine hydrochloride and chlorpheniramine maleate, sebum inhibitors such as estradiol, estrone and ethinyl estradiol Keratin exfoliating and dissolving agents such as salicylic acid and resorcin, antibacterial preservatives such as ethyl parahydroxybenzoate, methyl parahydroxybenzoate, butyl parahydroxybenzoate, propyl parahydroxybenzoate and ethylene glycol monophenyl ether,
Warming sensitizers such as glycerin and camphor, α-hydroxy acids and the like can be added.
【0023】さらに、細胞賦活,保湿,血行促進,抗炎
症,収れん,抗菌,抗酸化,皮脂抑制作用等の生理活性
を有するアルニカ,アロエ,イタドリ,イラクサ,ウイ
キョウ,エンメイソウ,オウバク,オランダガラシ,カ
キドオシ,カミツレ,カンゾウ,キナ,キンギンカ,キ
ュウリ,クジン,ゲンチアナ,ゲンノショウコ,ゴボ
ウ,コウスイハッカ,サンショウ,ジュウヤク,ショウ
キョウ,シラカンバ,スギナ,セイヨウキズタ,セイヨ
ウノコギリソウ,セージ,センブリ,タイム,チョウ
ジ,チンピ,トウガラシ,トウキンセンカ,トウキ,ト
ウヒ,ニンジン,ニンニク,ノイチゴ,パセリ,ハッ
カ,ハマボウフウ,ハマメリス,バラ,フキタンポポ,
ヘンナ,ボダイジュ,ホップ,ホホバ,マルメロ,マロ
ニエ,ヤグルマギク,ヤドリギ,ユーカリ,ユキノシ
タ,ユリ,ラベンダー,ローズマリー等の植物抽出物及
びこれらの抽出物の分画,精製物を血流促進剤と併用す
ることにより、相乗効果を発揮する。Furthermore, arnica, aloe, knotweed, nettle, fennel, gallgrass, oak, Dutch pepper, oysterfish have physiological activities such as cell activation, moisturizing, blood circulation promotion, anti-inflammatory, astringent, antibacterial, antioxidative and sebum suppressing action. , Chamomile, licorice, chrysanthemum, goldfish, cucumber, kujin, gentian, gennoshoko, burdock, koisu mint, salamander, sycamore, ginger, birch, horsetail, euglena, yarrow, sage, senburi, thyme, butterfly, Capsicum, spruce quince, spruce, spruce, carrot, garlic, strawberry, parsley, peppermint, hamaboufu, hamameris, rose, coltsfoot,
Plant extracts such as henna, bodaiju, hops, jojoba, quince, horse chestnut, cornflower, mistletoe, eucalyptus, yukinoshita, lily, lavender, rosemary, etc., and fractions and purified products of these extracts are used in combination with a blood flow promoter. By doing so, a synergistic effect is exhibited.
【0024】[0024]
【実施例】さらに本発明の特徴について、実施例により
詳細に説明する。EXAMPLES Further, the features of the present invention will be described in detail with reference to examples.
【0025】 [実施例1]液状皮膚外用剤 (1)グリセリン 5.0(重量%) (2)プロピレングリコール 4.0 (3)エタノール 10.0 (4)L−アルギニン ホスファチジルセリンエステル 0.5 (5)精製水 80.5 (4)を(3)に溶解して(5)に加え、(1),(2)を順次添加し、
混合,均一化する。[Example 1] Liquid external preparation for skin (1) Glycerin 5.0 (% by weight) (2) Propylene glycol 4.0 (3) Ethanol 10.0 (4) L-arginine phosphatidylserine ester 0.5 (5) Purified water 80.5 Dissolve (4) in (3) and add to (5), then add (1) and (2) sequentially,
Mix and homogenize.
【0026】 [実施例2]化粧水 (1)1,3-ブチレングリコール 3.0(重量%) (2)ソルビトール 2.0 (3)エタノール 10.0 (4)カルボキシビニルポリマー1重量%水溶液 10.0 (5)L−アルギニンラウリルエステル 0.3 (6)香料 0.1 (7)精製水 74.6 (6)を(3)に溶解して(7)に加え、(1),(2),(5)を順次添加
して混合した後、(4)を加え、混合,均一化する。[Example 2] Lotion (1) 1,3-butylene glycol 3.0 (wt%) (2) sorbitol 2.0 (3) ethanol 10.0 (4) carboxyvinyl polymer 1 wt% aqueous solution 10.0 (5) L-arginine lauryl ester 0.3 (6) Perfume 0.1 (7) Purified water 74.6 (6) is dissolved in (3) and added to (7), (1), After adding (2) and (5) sequentially and mixing, add (4) and mix and homogenize.
【0027】 [実施例3]O/W型乳剤性軟膏 (1)白色ワセリン 25.0(重量%) (2)ステアリルアルコール 15.0 (3)ラウリル硫酸ナトリウム 1.0 (4)パラオキシ安息香酸ブチル 0.1 (5)L−アルギニンコレステロールエステル 0.5 (6)精製水 58.4 (1)〜(4)の油相成分を混合し75℃に加熱して溶解,均
一化する。75℃に加熱した(6)に油相成分を添加して
乳化し、冷却後40℃にて(5)を添加,混合,均一化す
る。[Example 3] O / W type emulsion ointment (1) White petrolatum 25.0 (wt%) (2) Stearyl alcohol 15.0 (3) Sodium lauryl sulfate 1.0 (4) Paraoxybenzoic acid Butyl 0.1 (5) L-arginine cholesterol ester 0.5 (6) Purified water 58.4 The oil phase components of (1) to (4) are mixed and heated to 75 ° C. to dissolve and homogenize. The oil phase component is added to (6) heated to 75 ° C to emulsify, and after cooling, (5) is added, mixed and homogenized at 40 ° C.
【0028】 [実施例4]O/W乳化型美容液 (1)スクワラン 5.0(重量%) (2)白色ワセリン 2.0 (3)ミツロウ 0.5 (4)ソルビタンセスキオレエート 0.8 (5)ポリオキシエチレンオレイルエーテル(20EO) 1.2 (6)プロピレングリコール 5.0 (7)パラオキシ安息香酸メチル 0.1 (8)精製水 59.8 (9)カルボキシビニルポリマー1.0重量%水溶液 20.0 (10)水酸化カリウム 0.1 (11)エタノール 5.0 (12)L−アルギニンガラクトセレブロシド 0.3 (13)香料 0.2 (1)〜(5)の油相成分を混合し75℃に加熱して溶解,均
一化する。一方(6)〜(8)の水相成分を混合,溶解して7
5℃に加熱し、前記の油相成分を添加して予備乳化す
る。(9)を添加した後ホモミキサーにて均一に乳化し、
(10)を加えてpHを調整する。冷却後40℃にて(11)〜
(13)を添加,混合,均一化する。[Example 4] O / W emulsion type beauty essence (1) Squalane 5.0 (% by weight) (2) White petrolatum 2.0 (3) Beeswax 0.5 (4) Sorbitan sesquioleate 0. 8 (5) Polyoxyethylene oleyl ether (20EO) 1.2 (6) Propylene glycol 5.0 (7) Methyl paraoxybenzoate 0.1 (8) Purified water 59.8 (9) Carboxyvinyl polymer 1.0% by weight Aqueous solution 20.0 (10) Potassium hydroxide 0.1 (11) Ethanol 5.0 (12) L-Arginine galactocerebroside 0.3 (13) Perfume 0.2 Add oil phase components of (1) to (5) Mix and heat to 75 ° C to dissolve and homogenize. On the other hand, mix (6) to (8) water phase components and dissolve to
The mixture is heated to 5 ° C., the above oil phase component is added, and pre-emulsified. After adding (9), emulsify uniformly with a homomixer,
(10) is added to adjust the pH. After cooling at 40 ℃ (11) ~
Add (13), mix, and homogenize.
【0029】 [実施例5]W/O乳化型クリーム (1)ミツロウ 3.0(重量%) (2)吸着精製ラノリン 10.0 (3)スクワラン 30.0 (4)固形パラフィン 2.0 (5)マイクロクリスタリンワックス 5.0 (6)アジピン酸ヘキシルデシル 10.0 (7)セスキオレイン酸ソルビタン 3.5 (8)ポリオキシエチレン硬化ヒマシ油(50EO) 1.0 (9)1,3-ブチレングリコール 5.0 (10)精製水 29.3 (11)パラオキシ安息香酸メチル 0.2 (12)L−アルギニンオクチルエステル 1.0 (1)〜(8)の油相成分を混合し75℃に加熱して溶解,均
一化する。一方(9)〜(11)の水相成分を混合,溶解して
75℃に加熱し、前記の油相成分に添加してホモミキサ
ーにて均一に乳化する。冷却後40℃にて(12)を添加,
混合する。[Example 5] W / O emulsion type cream (1) Beeswax 3.0 (wt%) (2) Adsorption-purified lanolin 10.0 (3) Squalane 30.0 (4) Solid paraffin 2.0 ( 5) Microcrystalline wax 5.0 (6) Hexyldecyl adipate 10.0 (7) Sorbitan sesquioleate 3.5 (8) Polyoxyethylene hydrogenated castor oil (50EO) 1.0 (9) 1,3- Butylene glycol 5.0 (10) Purified water 29.3 (11) Methyl paraoxybenzoate 0.2 (12) L-arginine octyl ester 1.0 Mix the oil phase components of (1) to (8) at 75 ° C. Heat to dissolve and homogenize. On the other hand, the aqueous phase components (9) to (11) are mixed and dissolved, heated to 75 ° C., added to the above oil phase components, and uniformly emulsified by a homomixer. After cooling, add (12) at 40 ℃,
Mix.
【0030】 [実施例6]O/W乳液 (1)ミツロウ 0.7(重量%) (2)スクワラン 5.0 (3)ポリオキシエチレン硬化ヒマシ油(50EO) 2.0 (4)精製水 61.8 (5)1,3-ブチレングリコール 5.0 (6)パラオキシ安息香酸メチル 0.2 (7)1%カルボキシメチルセルロース水溶液 20.0 (8)エタノール 5.0 (9)L−アルギニングルコシド 0.3 (1)〜(3)の油相成分を混合,溶解して均一とし、75℃
に加熱する。一方、(4)〜(6)を混合,溶解して75℃に
加熱し、これに上記油相成分を添加して予備乳化した
後、(7)を加えてホモミキサーにて均一に乳化する。そ
の後冷却し、40℃で、(8),(9)を添加する。Example 6 O / W Emulsion (1) Beeswax 0.7 (wt%) (2) Squalane 5.0 (3) Polyoxyethylene hydrogenated castor oil (50EO) 2.0 (4) Purified water 61.8 (5) 1,3-Butylene glycol 5.0 (6) Methyl paraoxybenzoate 0.2 (7) 1% aqueous carboxymethylcellulose solution 20.0 (8) Ethanol 5.0 (9) L-arginine glucoside 0.3 (1) ~ (3) oil phase components are mixed and dissolved to homogenize, 75 ℃
Heat to On the other hand, (4) to (6) are mixed, dissolved and heated to 75 ° C., the above oil phase component is added to the mixture for preliminary emulsification, and then (7) is added and uniformly emulsified with a homomixer. . After cooling, (8) and (9) are added at 40 ° C.
【0031】 [実施例7]ローションタイプ養毛剤 (1)1,3−ブチレングリコール 2.0(重量%) (2)グリセリン 1.0 (3)塩化ステアリルトリメチルアンモニウム 0.5 (4)メチルフェニルポリシロキサン 1.0 (5)コラーゲン加水分解物 1.0 (6)エタノール 50.0 (7)パラオキシ安息香酸メチル 0.2 (8)精製水 43.8 (11)L−アルギニンリゾホスファチジン酸エステル 0.5 (1)〜(12)の全成分を混合均一化する。[Example 7] Lotion type hair nourishing agent (1) 1,3-butylene glycol 2.0 (% by weight) (2) glycerin 1.0 (3) stearyl trimethyl ammonium chloride 0.5 (4) methylphenyl poly Siloxane 1.0 (5) Collagen hydrolyzate 1.0 (6) Ethanol 50.0 (7) Methyl paraoxybenzoate 0.2 (8) Purified water 43.8 (11) L-arginine lysophosphatidic acid ester 0 .5 Mix and homogenize all components (1) to (12).
【0032】本発明の実施例及び、−アルギニンエステ
ルを等モルのL−アルギニンに置き換えた比較例を用い
て、マウスの血流促進効果の測定を行った。剃毛したマ
ウス背部に実施例及び比較例を塗布し、塗布前及び塗布
後15分後の血流量の測定を行った。結果を表1に示し
た。その結果、L−アルギニンをエステル化して配合し
た実施例は、比較例よりも1.5倍程度の血流促進効果
を有していた。このことにより、L−アルギニンをエス
テル化して配合することで、L−アルギニンの経皮透過
性が高まり、少量の配合で、有効な血流促進効果が得ら
れることがわかった。Using the example of the present invention and a comparative example in which -arginine ester was replaced with equimolar L-arginine, the blood flow promoting effect in mice was measured. The Example and Comparative Example were applied to the shaved back of the mouse, and blood flow was measured before and 15 minutes after the application. The results are shown in Table 1. As a result, the example in which L-arginine was esterified and mixed had a blood flow promoting effect of about 1.5 times that of the comparative example. From this, it was found that by esterifying and blending L-arginine, the transdermal permeability of L-arginine was increased, and an effective blood flow promoting effect was obtained with a small amount of blending.
【表1】 [Table 1]
【0033】実施例2及び実施例2のL−アルギニンエ
ステルを精製水に置き換えた比較例A、L−アルギニン
エステルを等モルのL−アルギニンに置き換えた比較例
Bを用いて官能評価を行った。官能評価は、シワ等の老
化症状の気になるパネル各10人に実施例2及び比較例
A,Bをそれぞれ1日2回,3カ月間連続使用してもら
い、3カ月後の肌状態についてアンケート調査を行っ
た。官能評価の結果を表2に示した。評価結果は、各項
目の回答人数で示した。Sensory evaluation was carried out using Comparative Example A in which the L-arginine ester of Example 2 and Example 2 was replaced by purified water, and Comparative Example B in which the L-arginine ester was replaced by an equimolar amount of L-arginine. . The sensory evaluation was carried out by having 10 people each worried about aging symptoms such as wrinkles use Example 2 and Comparative Examples A and B twice a day for 3 months continuously and about the skin condition after 3 months. We conducted a questionnaire survey. The results of sensory evaluation are shown in Table 2. The evaluation results are shown by the number of respondents in each item.
【0034】[0034]
【表2】 官能評価の結果、実施例2ではほとんどのパネルで、シ
ワ,ハリ,ツヤ,タルミに改善効果が認められた。一方
比較例Aでは、効果があるとしたパネルの数はどの項目
でも20%未満であり 老化症状改善効果はほとんど認
められなかった。L−アルギニンを配合した比較例Bで
は、改善効果があると回答したパネルの数は50%程度
に増加していたが、実施例2の改善効果にははるかに及
ばない結果となった。このことにより、L−アルギニン
をエステル化して配合することにより、シワ,ハリ,ツ
ヤ,タルミ等の皮膚老化症状を改善する効果が飛躍的に
向上することが示された。[Table 2] As a result of the sensory evaluation, in almost all of the panels in Example 2, the effect of improving wrinkles, firmness, gloss and tarmi was observed. On the other hand, in Comparative Example A, the number of panels determined to be effective was less than 20% in any item, and almost no effect of improving aging symptoms was observed. In Comparative Example B containing L-arginine, the number of panels that answered that there was an improving effect increased to about 50%, but the result was far below the improving effect of Example 2. From this, it was shown that the effect of improving skin aging symptoms such as wrinkles, firmness, gloss, and tarmi is dramatically improved by esterifying and blending L-arginine.
【0035】また、実施例7のローションタイプ養毛剤
について、マウスを用いて養毛効果試験を行った。休止
期にあるC3系マウス(1群5匹)の背部を剃毛し、実
施例7のローションタイプ養毛剤をそれぞれ1日1回塗
布し、剃毛後20日における再生毛面積比(再生毛面積
/剃毛面積)を測定した。比較例として、L−アルギニ
ンエステルを等モルのL−アルギニンに置き換えてロー
ションタイプ育毛剤を調製し、実施例と同様の操作を行
った。結果を表3に示した。Further, the lotion-type hair nourishing agent of Example 7 was subjected to a hair nourishing effect test using mice. The backs of C3 mice (5 mice per group) in the resting phase were shaved, and the lotion-type hair nourishing agent of Example 7 was applied once a day, respectively, and the ratio of regenerated hair area 20 days after shaving (regenerated hair area) / Shaving area) was measured. As a comparative example, an L-arginine ester was replaced with an equimolar amount of L-arginine to prepare a lotion-type hair restorer, and the same operation as in Example was performed. The results are shown in Table 3.
【0036】[0036]
【表3】 表3に示す結果より明らかなように、本発明の実施例7
の再生毛面積比は、0.8以上の値を示しており、比較
例に比べ、顕著な毛の再生が見られることがわかる。[Table 3] As is clear from the results shown in Table 3, Example 7 of the present invention
The ratio of regenerated hair area is 0.8 or more, which shows that remarkable regenerated hair is observed as compared with the comparative example.
【0037】なお、上記の使用期間において、実施例を
使用した群において、痛み、痒み等の皮膚刺激やアレル
ギー反応等の皮膚症状を訴えたパネラーはいなかった。
また、乳化状態の悪化や配合成分の沈降,変質等も認め
られなかった。During the above-mentioned period of use, no panelists complained of skin irritation such as pain and itching, or skin symptoms such as allergic reaction in the group using the examples.
In addition, no deterioration of the emulsified state, no sedimentation and deterioration of the components were observed.
【0038】[0038]
【発明の効果】以上詳述したように、本発明により、L
−アルギニンエステルを血流促進剤として配合すること
により、非常に優れた老化防止効果及び養毛効果を発揮
する皮膚外用剤を提供することができる。本発明に係る
皮膚外用剤においては、有効成分であるL−アルギニン
が良好に経皮吸収され、表皮基底層からさらには真皮に
まで到達でき、低濃度の配合で優れた老化防止効果及び
養毛効果を示すものと考えられる。As described above in detail, according to the present invention, L
By blending arginine ester as a blood flow promoting agent, a skin external preparation that exhibits a very excellent anti-aging effect and hair-growth effect can be provided. In the external preparation for skin according to the present invention, L-arginine, which is an active ingredient, is satisfactorily transdermally absorbed, can reach the dermis from the epidermis basal layer, and has excellent anti-aging effect and hair growth with a low concentration. It is considered to show an effect.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 7/06 A61K 7/06 7/48 7/48 31/575 31/575 31/66 ADS 31/66 ADS 31/685 ADA 31/685 ADA 31/70 31/70 C07H 15/04 C07H 15/04 D C07J 9/00 C07J 9/00 ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical display area A61K 7/06 A61K 7/06 7/48 7/48 31/575 31/575 31/66 ADS 31 / 66 ADS 31/685 ADA 31/685 ADA 31/70 31/70 C07H 15/04 C07H 15/04 D C07J 9/00 C07J 9/00
Claims (6)
ル若しくはアルケニルエステル、リン脂質エステル、ス
フィンゴシン及びその誘導体のエステル、糖脂質エステ
ル、糖エステル、ステロールエステルを有効成分とする
血流促進剤。1. A blood flow promoter comprising an alkyl or alkenyl ester of L-arginine having 6 to 20 carbon atoms, a phospholipid ester, an ester of sphingosine and its derivative, a glycolipid ester, a sugar ester, or a sterol ester as an active ingredient.
して配合した皮膚外用剤。2. A skin external preparation containing the blood flow promoting agent according to claim 1 as an active ingredient.
して配合した化粧料。3. A cosmetic containing the blood flow promoter according to claim 1 as an active ingredient.
して配合した老化防止用化粧料。4. A cosmetic for anti-aging containing the blood flow promoter according to claim 1 as an active ingredient.
して配合した頭皮用化粧料。5. A scalp cosmetic containing the blood flow promoter according to claim 1 as an active ingredient.
して配合した養毛・育毛剤。6. A hair nourishing and hair-growing agent containing the blood flow promoting agent according to claim 1 as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP07966696A JP4020989B2 (en) | 1996-03-06 | 1996-03-06 | Blood flow promoting agent and external preparation for skin comprising the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP07966696A JP4020989B2 (en) | 1996-03-06 | 1996-03-06 | Blood flow promoting agent and external preparation for skin comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09241156A true JPH09241156A (en) | 1997-09-16 |
JP4020989B2 JP4020989B2 (en) | 2007-12-12 |
Family
ID=13696502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP07966696A Expired - Fee Related JP4020989B2 (en) | 1996-03-06 | 1996-03-06 | Blood flow promoting agent and external preparation for skin comprising the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4020989B2 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999045900A1 (en) * | 1998-03-11 | 1999-09-16 | Kabushiki Kaisha Soken | Skin normalizing agents |
JP2000327560A (en) * | 1999-05-18 | 2000-11-28 | Noevir Co Ltd | Bathing agent composition |
JP2001026514A (en) * | 1999-06-16 | 2001-01-30 | Exsymol Sam | Cosmetic composition for slimming |
WO2001055098A1 (en) * | 2000-01-28 | 2001-08-02 | The Procter & Gamble Company | Palatable arginine compounds and uses thereof for cardiovascular health |
JP2002003373A (en) * | 2000-06-27 | 2002-01-09 | Shiseido Co Ltd | Skin care preparation |
JP2006273808A (en) * | 2005-03-30 | 2006-10-12 | Naris Cosmetics Co Ltd | Whitening cosmetics |
WO2006109888A1 (en) * | 2005-04-13 | 2006-10-19 | Shiseido Company, Ltd. | Antiwrinkle agent |
EP1714650A1 (en) * | 2005-03-31 | 2006-10-25 | Ajinomoto Co., Inc. | Arginine-containing compositions for increasing blood flow |
JP2006306865A (en) * | 2005-03-31 | 2006-11-09 | Ajinomoto Co Inc | Arginine-containing composition for increasing blood flow |
JP2009526753A (en) * | 2005-12-30 | 2009-07-23 | ルバンス セラピュティックス インク. | Arginine heteromer for topical administration |
AU2006203098B2 (en) * | 1998-03-11 | 2009-10-08 | Kabushiki Kaisha Soken | Skin conditioner |
JP2009242396A (en) * | 2008-03-28 | 2009-10-22 | L'oreal Sa | Composition containing combination of madecassoside and/or terminoloside, as well as arginine and/or salt and/or derivative thereof; use of the combination for inducing and/or stimulating growth of human keratinous fiber, and/or for preventing loss of human keratinous fiber |
US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US7829593B2 (en) | 2006-09-29 | 2010-11-09 | Ajinomoto Co., Inc. | Glutamine-containing compositions and a method for increasing blood flow using same |
US7914814B2 (en) | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
WO2013017361A1 (en) * | 2011-08-03 | 2013-02-07 | Evonik Goldschmidt Gmbh | Use of sphinganine to improve the visual appearance of skin and hair |
US9050365B2 (en) | 2004-04-19 | 2015-06-09 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US9072659B2 (en) | 2009-06-24 | 2015-07-07 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
US9155701B2 (en) | 2009-06-24 | 2015-10-13 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
US9381146B2 (en) | 1998-03-11 | 2016-07-05 | Kabushiki Kaisha Soken | Skin conditioner |
US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
JP2019137650A (en) * | 2018-02-14 | 2019-08-22 | 株式会社 リトル・サイエンティスト | Cosmetic containing arginine ester |
WO2022265054A1 (en) * | 2021-06-19 | 2022-12-22 | 株式会社アジュバンホールディングス | Hair growth stimulant |
WO2022265053A1 (en) * | 2021-06-19 | 2022-12-22 | 株式会社アジュバンホールディングス | Hair growth stimulant |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US12138268B2 (en) | 2009-06-24 | 2024-11-12 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
-
1996
- 1996-03-06 JP JP07966696A patent/JP4020989B2/en not_active Expired - Fee Related
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7914814B2 (en) | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US9381146B2 (en) | 1998-03-11 | 2016-07-05 | Kabushiki Kaisha Soken | Skin conditioner |
WO1999045900A1 (en) * | 1998-03-11 | 1999-09-16 | Kabushiki Kaisha Soken | Skin normalizing agents |
AU2006203098B2 (en) * | 1998-03-11 | 2009-10-08 | Kabushiki Kaisha Soken | Skin conditioner |
JP2000327560A (en) * | 1999-05-18 | 2000-11-28 | Noevir Co Ltd | Bathing agent composition |
JP2001026514A (en) * | 1999-06-16 | 2001-01-30 | Exsymol Sam | Cosmetic composition for slimming |
WO2001055098A1 (en) * | 2000-01-28 | 2001-08-02 | The Procter & Gamble Company | Palatable arginine compounds and uses thereof for cardiovascular health |
US6794375B2 (en) * | 2000-01-28 | 2004-09-21 | The Procter & Gamble Co. | Palatable arginine compounds and uses thereof for cardiovascular health |
JP2002003373A (en) * | 2000-06-27 | 2002-01-09 | Shiseido Co Ltd | Skin care preparation |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US9050365B2 (en) | 2004-04-19 | 2015-06-09 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
JP2006273808A (en) * | 2005-03-30 | 2006-10-12 | Naris Cosmetics Co Ltd | Whitening cosmetics |
JP2006306865A (en) * | 2005-03-31 | 2006-11-09 | Ajinomoto Co Inc | Arginine-containing composition for increasing blood flow |
US8445536B2 (en) | 2005-03-31 | 2013-05-21 | Ajinomoto Co., Inc. | Arginine-containing compositions and methods for increasing blood flow using same |
EP1714650A1 (en) * | 2005-03-31 | 2006-10-25 | Ajinomoto Co., Inc. | Arginine-containing compositions for increasing blood flow |
WO2006109888A1 (en) * | 2005-04-13 | 2006-10-19 | Shiseido Company, Ltd. | Antiwrinkle agent |
KR101496373B1 (en) * | 2005-12-30 | 2015-02-26 | 레반스 테라퓨틱스, 아이엔씨. | Arginine heteromer for topical administration |
US8628756B2 (en) | 2005-12-30 | 2014-01-14 | Revance Therapeutics, Inc. | Arginine heteromers for topical administration |
JP2013028633A (en) * | 2005-12-30 | 2013-02-07 | Revance Therapeutics Inc | Arginine heteromer for use in topical administration |
US8815954B2 (en) * | 2005-12-30 | 2014-08-26 | Revance Therapeutics, Inc. | Arginine heteromers for topical administration |
JP2009526753A (en) * | 2005-12-30 | 2009-07-23 | ルバンス セラピュティックス インク. | Arginine heteromer for topical administration |
US7829593B2 (en) | 2006-09-29 | 2010-11-09 | Ajinomoto Co., Inc. | Glutamine-containing compositions and a method for increasing blood flow using same |
JP2009242396A (en) * | 2008-03-28 | 2009-10-22 | L'oreal Sa | Composition containing combination of madecassoside and/or terminoloside, as well as arginine and/or salt and/or derivative thereof; use of the combination for inducing and/or stimulating growth of human keratinous fiber, and/or for preventing loss of human keratinous fiber |
US9457092B2 (en) | 2009-06-24 | 2016-10-04 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US10898489B2 (en) | 2009-06-24 | 2021-01-26 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9161915B2 (en) | 2009-06-24 | 2015-10-20 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US9072659B2 (en) | 2009-06-24 | 2015-07-07 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
US12138268B2 (en) | 2009-06-24 | 2024-11-12 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9155701B2 (en) | 2009-06-24 | 2015-10-13 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9492458B2 (en) | 2009-06-24 | 2016-11-15 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US10682357B2 (en) | 2009-06-24 | 2020-06-16 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9675619B2 (en) | 2009-06-24 | 2017-06-13 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9737543B2 (en) | 2009-06-24 | 2017-08-22 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US10172865B2 (en) | 2009-06-24 | 2019-01-08 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9833456B2 (en) | 2010-12-29 | 2017-12-05 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9498482B2 (en) | 2010-12-29 | 2016-11-22 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
CN103764108A (en) * | 2011-08-03 | 2014-04-30 | 赢创德固赛有限公司 | Use of sphinganine to improve the visual appearance of skin and hair |
WO2013017361A1 (en) * | 2011-08-03 | 2013-02-07 | Evonik Goldschmidt Gmbh | Use of sphinganine to improve the visual appearance of skin and hair |
JP2019137650A (en) * | 2018-02-14 | 2019-08-22 | 株式会社 リトル・サイエンティスト | Cosmetic containing arginine ester |
WO2022265054A1 (en) * | 2021-06-19 | 2022-12-22 | 株式会社アジュバンホールディングス | Hair growth stimulant |
WO2022265053A1 (en) * | 2021-06-19 | 2022-12-22 | 株式会社アジュバンホールディングス | Hair growth stimulant |
Also Published As
Publication number | Publication date |
---|---|
JP4020989B2 (en) | 2007-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4020989B2 (en) | Blood flow promoting agent and external preparation for skin comprising the same | |
EP1600143B1 (en) | SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE | |
KR101355343B1 (en) | Skin treatment composition | |
KR100881611B1 (en) | External preparation | |
WO2008110942A1 (en) | Cosmetic formulations | |
RU2442563C2 (en) | The compositions containing the proteins for the transfer/recycling the structurally modified lipids and their application | |
KR20030026233A (en) | Skin cleanser containing anti-aging active | |
JP3758794B2 (en) | Collagen production promoter and anti-aging skin external preparation containing the same | |
WO2002083087A1 (en) | Sugar intake promoters | |
JPH06305932A (en) | Skin external agent | |
JPH0995432A (en) | Preparation for external use for skin | |
JPH04270212A (en) | Skin external agent | |
JP3568983B2 (en) | Hair restorer | |
JP3505003B2 (en) | External preparation | |
JPH07215839A (en) | Skin external agent | |
JP4193016B2 (en) | Skin preparation | |
JP2004131403A (en) | Skin care preparation for external use | |
JPH07138125A (en) | Dermal agent for external use | |
CA2508093A1 (en) | Preparation for external use on skin | |
JP2001302435A (en) | External preparation for skin | |
JP3526497B2 (en) | Body composition | |
JP2000256167A (en) | Skin lotion | |
JPH07215832A (en) | Skin external preparation | |
JPH11255617A (en) | Makeup cosmetic for improving skin condition | |
JPH10147514A (en) | Cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070213 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070413 |
|
RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7425 Effective date: 20070413 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070920 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070926 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101005 Year of fee payment: 3 |
|
R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101005 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111005 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111005 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121005 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121005 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131005 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |